UHLMANN PRICE SECURITIES’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-16
Closed -$4.33K 303
2026
Q1
$4.33K Sell
16
-1,584
-99% -$42.2K ﹤0.01% 254
2025
Q4
$1.49K Buy
+1,600
New +$40.3K ﹤0.01% 197
2025
Q3
Sell
-800
Closed -$278 201
2025
Q2
$278 Sell
800
-300
-27% -$7K ﹤0.01% 187
2025
Q1
$486 Buy
1,100
+600
+120% +$15.7K ﹤0.01% 188
2024
Q4
$368 Sell
500
-200
-29% -$5.42K ﹤0.01% 179
2024
Q3
$1.26K Buy
+700
New +$20.4K ﹤0.01% 179

Other funds holding PFE

UHLMANN PRICE SECURITIES's PFE Position: Q2 2026 in Review

UHLMANN PRICE SECURITIES increased its Pfizer (PFE) stake by 6.4% in Q2 2026, buying an estimated $59.2K and bringing the position to 37,865 shares worth $912K. The position accounts for 0.03% of the portfolio, ranked #85.

UHLMANN PRICE SECURITIES first reported a position in PFE in Q3 2024 and has held it in 8 quarters since. The position peaked at $976K in Q1 2026. 1,257 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • UHLMANN PRICE SECURITIES held 37,865 shares of Pfizer worth $912K as of Q2 2026.
  • UHLMANN PRICE SECURITIES bought 2,263 Pfizer shares in Q2 2026, an estimated $59.2K.
  • Pfizer made up 0.03% of UHLMANN PRICE SECURITIES's portfolio in Q2 2026, its #85 holding.
  • UHLMANN PRICE SECURITIES first reported a position in Pfizer in Q3 2024 and has held it in 8 quarters since.
  • UHLMANN PRICE SECURITIES's Pfizer position peaked at $976K in Q1 2026.
  • 1,257 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on UHLMANN PRICE SECURITIES's 13F filing for Q2 2026, filed 24 Jul 2026.